Patient-reported outcome | Placebo (n=88) | Apremilast BID | ||
---|---|---|---|---|
 |  | 10 mg (n=89) | 20 mg (n=86) | 30 mg (n=88) |
DLQI | Â | Â | Â | Â |
   Baseline | 10.7 ± 6.7 | 10.8 ± 6.3 | 11.6 ± 7.0 | 10.6 ± 6.2 |
   Week 16 | 8.6 ± 7.6 | 7.6 ± 6.3 | 5.8 ± 6.0 | 6.0 ± 6.2 |
   Change from baseline | −1.9 ± 5.2 | −3.2 ± 6.0 | −5.9 ± 6.7* | −4.4 ± 5.1* |
Pruritus VAS | Â | Â | Â | Â |
   Baseline | 55.5 ± 25.5 | 54.1 ± 23.5 | 58.3 ± 26.7 | 55.3 ± 25.5 |
   Week 16 | 45.6 ± 30.2 | 39.0 ± 27.8 | 35.2 ± 29.2 | 31.6 ± 30.0 |
   Percent change from baseline | −6.1 ± 76.4 | −10.2 ± 100.8 | −35.5 ± 66.0* | −43.7 ± 46.8* |